ES2674129T3 - Agentes terapéuticos de base aptámeros útiles en el tratamiento de trastornos relacionados con complemento - Google Patents

Agentes terapéuticos de base aptámeros útiles en el tratamiento de trastornos relacionados con complemento Download PDF

Info

Publication number
ES2674129T3
ES2674129T3 ES14194459.5T ES14194459T ES2674129T3 ES 2674129 T3 ES2674129 T3 ES 2674129T3 ES 14194459 T ES14194459 T ES 14194459T ES 2674129 T3 ES2674129 T3 ES 2674129T3
Authority
ES
Spain
Prior art keywords
aptamer
complement
treatment
therapeutic agents
related disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14194459.5T
Other languages
English (en)
Inventor
Claude Benedict
John Deiner
David Epstein
Dilara Grate
Sara Chesworth Keene
Jeffrey Kurz
Markus Kurz
Thomas Green Mccauley
James Rottman
Kristin Thompson
Charles Wilson
Anna J. Zoltoski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Archemix LLC
Original Assignee
Archemix LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archemix LLC filed Critical Archemix LLC
Application granted granted Critical
Publication of ES2674129T3 publication Critical patent/ES2674129T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/317—Chemical structure of the backbone with an inverted bond, e.g. a cap structure
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)

Abstract

Un aptámero o una sal del mismo, en el que el aptámero es: **Fórmula** en el que fC y fU >= 2'-fluoro nucleótidos, mG y mA >= 2'-OMe nucleótidos y todos los demás nucleótidos son 2'-OH y 3T indica una desoxitimidina invertida.
ES14194459.5T 2004-02-12 2005-02-14 Agentes terapéuticos de base aptámeros útiles en el tratamiento de trastornos relacionados con complemento Active ES2674129T3 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US54454204P 2004-02-12 2004-02-12
US544542P 2004-02-12
US54774704P 2004-02-25 2004-02-25
US547747P 2004-02-25
US58168504P 2004-06-21 2004-06-21
US581685P 2004-06-21
US60804804P 2004-09-07 2004-09-07
US608048P 2004-09-07

Publications (1)

Publication Number Publication Date
ES2674129T3 true ES2674129T3 (es) 2018-06-27

Family

ID=34891329

Family Applications (4)

Application Number Title Priority Date Filing Date
ES18156968T Active ES2808955T3 (es) 2004-02-12 2005-02-14 Agentes terapéuticos de base aptámeros útiles en el tratamiento de trastornos relacionados con complemento
ES14194459.5T Active ES2674129T3 (es) 2004-02-12 2005-02-14 Agentes terapéuticos de base aptámeros útiles en el tratamiento de trastornos relacionados con complemento
ES05713496T Active ES2429442T3 (es) 2004-02-12 2005-02-14 Aptámeros terapéuticos útiles en el tratamiento de trastornos relacionados con complemento
ES13150168T Active ES2531075T3 (es) 2004-02-12 2005-02-14 Agentes terapéuticos de base aptámeros útiles en el tratamiento de trastornos relacionados con complemento

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES18156968T Active ES2808955T3 (es) 2004-02-12 2005-02-14 Agentes terapéuticos de base aptámeros útiles en el tratamiento de trastornos relacionados con complemento

Family Applications After (2)

Application Number Title Priority Date Filing Date
ES05713496T Active ES2429442T3 (es) 2004-02-12 2005-02-14 Aptámeros terapéuticos útiles en el tratamiento de trastornos relacionados con complemento
ES13150168T Active ES2531075T3 (es) 2004-02-12 2005-02-14 Agentes terapéuticos de base aptámeros útiles en el tratamiento de trastornos relacionados con complemento

Country Status (14)

Country Link
US (2) US7538211B2 (es)
EP (5) EP3736335A1 (es)
JP (1) JP5242918B2 (es)
CY (3) CY1114443T1 (es)
DK (3) DK2860251T3 (es)
ES (4) ES2808955T3 (es)
HK (2) HK1183896A1 (es)
HU (2) HUE038239T2 (es)
LT (2) LT2860251T (es)
PL (2) PL2860251T3 (es)
PT (3) PT2860251T (es)
SI (2) SI3385384T1 (es)
TR (1) TR201808488T4 (es)
WO (1) WO2005079363A2 (es)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US7300922B2 (en) * 2001-05-25 2007-11-27 Duke University Modulators of pharmacological agents
EP1615945B1 (en) 2003-04-09 2011-09-28 BioGeneriX AG Glycopegylation methods and proteins/peptides produced by the methods
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US7803931B2 (en) * 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders
US20080300173A1 (en) 2004-07-13 2008-12-04 Defrees Shawn Branched Peg Remodeling and Glycosylation of Glucagon-Like Peptides-1 [Glp-1]
HUE026826T2 (en) 2004-10-29 2016-07-28 Ratiopharm Gmbh Modeling and glycopegylation of fibroblast growth factor (FGF)
ES2449195T3 (es) 2005-01-10 2014-03-18 Ratiopharm Gmbh Factor estimulante de colonias de granulocitos glicopegilado
WO2006121569A2 (en) 2005-04-08 2006-11-16 Neose Technologies, Inc. Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
US20090305967A1 (en) * 2005-08-19 2009-12-10 Novo Nordisk A/S Glycopegylated factor vii and factor viia
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
GB0518443D0 (en) 2005-09-09 2005-10-19 Evolutec Ltd Method of treating myasthenia gravis
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
CA2633063A1 (en) * 2005-12-16 2007-06-21 Diatos Cell penetrating peptide conjugates for delivering of nucleic acids intocells
HUE026496T2 (en) * 2006-03-08 2016-06-28 Archemix Llc Complement-binding aptamers and anti-C5 agents for treating eye diseases
ES2516694T3 (es) 2006-07-21 2014-10-31 Ratiopharm Gmbh Glicosilación de péptidos a través de secuencias de glicosilación con unión en O
US8969532B2 (en) 2006-10-03 2015-03-03 Novo Nordisk A/S Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography
DK2148691T3 (en) 2007-02-05 2015-08-17 Apellis Pharmaceuticals Inc Compstatinanaloger for use in the treatment of inflammatory states of the respiratory system
EP2129681A2 (en) * 2007-03-22 2009-12-09 Novartis Ag C5 antigens and uses thereof
PL2144923T3 (pl) 2007-04-03 2013-12-31 Biogenerix Ag Sposoby leczenia z użyciem glikopegilowanego G-CSF
WO2008134077A1 (en) * 2007-04-30 2008-11-06 Archemix Corp. Metabolic profile directed aptamer medicinal chemistry
US9493499B2 (en) 2007-06-12 2016-11-15 Novo Nordisk A/S Process for the production of purified cytidinemonophosphate-sialic acid-polyalkylene oxide (CMP-SA-PEG) as modified nucleotide sugars via anion exchange chromatography
CN101809154A (zh) * 2007-09-24 2010-08-18 诺松制药股份公司 C5a结合核酸
WO2009067549A1 (en) * 2007-11-19 2009-05-28 Allegiance Corporation Patient interface assembly for respiratory therapy
WO2009073820A2 (en) * 2007-12-04 2009-06-11 Archemix Corp. Biopolymer-nucleic acid conjugation
WO2009108806A1 (en) 2008-02-27 2009-09-03 Novo Nordisk A/S Conjugated factor viii molecules
WO2010108657A2 (en) * 2009-03-23 2010-09-30 Noxxon Pharma Ag C5a binding nucleic acids and the use thereof
US8841429B2 (en) 2009-11-03 2014-09-23 Vivonics, Inc. Nucleic acid ligands against infectious prions
US8236570B2 (en) 2009-11-03 2012-08-07 Infoscitex Methods for identifying nucleic acid ligands
EP2468295A1 (en) * 2010-12-21 2012-06-27 Affiris AG Vaccines based on peptides of the complement protein C5a
EP2723361B1 (en) 2011-06-22 2019-10-30 Apellis Pharmaceuticals, Inc. Methods of treating chronic disorders with complement inhibitors
PT2802660T (pt) 2012-01-10 2020-04-21 Aptarion Biotech Ag Novos ácidos nucleicos que se ligam a c5a
EP2666785A1 (en) * 2012-05-23 2013-11-27 Affiris AG Complement component C5a-based vaccine
SI3660033T1 (sl) 2012-11-15 2021-09-30 Apellis Pharmaceuticals, Inc. Analogi kompstatina z dolgotrajnim delovanjem in sorodni sestavki in postopki
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
WO2014160958A1 (en) 2013-03-29 2014-10-02 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
JP6968787B2 (ja) 2015-10-07 2021-11-17 アペリス・ファーマシューティカルズ・インコーポレイテッドApellis Pharmaceuticals, Inc. 投与レジメン
EP3411400B1 (en) 2017-04-03 2021-09-22 InflaRx GmbH Treatment of inflammatory diseases with inhibitors of c5a activity
US10376595B2 (en) 2017-04-03 2019-08-13 Inflarx Gmbh Treatment of inflammatory diseases with inhibitors of C5a activity
KR20190139931A (ko) 2017-04-07 2019-12-18 아펠리스 파마슈티컬스 인코포레이티드 투여 요법 및 관련 조성물 및 방법
US10450345B2 (en) 2017-06-09 2019-10-22 General Electric Company Method of isolation of polypeptide-aptamer-polymer conjugates
CN111201241A (zh) 2017-06-23 2020-05-26 因弗拉克斯有限责任公司 用C5a活性抑制剂治疗炎性疾病
RU2703799C1 (ru) * 2018-05-31 2019-10-22 Федеральное государственное бюджетное образовательное учреждение высшего образования "Московский государственный университет имени М.В. Ломоносова" (МГУ) Днк-аптамеры, взаимодействующие с протромбином
US20220356234A1 (en) 2019-10-02 2022-11-10 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
US20230158060A1 (en) 2020-03-27 2023-05-25 Inflarx Gmbh Inhibitors of C5a for the Treatment of Corona Virus Infection
EP4150338A1 (en) 2020-05-15 2023-03-22 Alexion Pharmaceuticals, Inc. Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
US4959309A (en) 1983-07-14 1990-09-25 Molecular Diagnostics, Inc. Fast photochemical method of labelling nucleic acids for detection purposes in hybridization assays
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
EP0590689B2 (fr) 1985-03-30 2006-08-16 KAUFFMAN, Stuart A. Procédé d'obtention d'ADN, ARN, peptides, polypeptides ou protéines, par une technique de recombinaison d'ADN
GB2181661B (en) 1985-10-22 1989-09-20 Nat Res Dev Improvements in or relating to apparatus for removing settled sludge from liquid
US4935363A (en) 1987-03-30 1990-06-19 Board Of Regents, The University Of Texas System Sterol regulatory elements
WO1989006694A1 (en) 1988-01-15 1989-07-27 Trustees Of The University Of Pennsylvania Process for selection of proteinaceous substances which mimic growth-inducing molecules
US5070010A (en) 1989-10-30 1991-12-03 Hoffman-La Roche Inc. Method for determining anti-viral transactivating activity
CA2078659A1 (en) 1990-03-21 1991-09-22 David J. Ecker Reagents and methods for modulating gene expression through rna mimicry
US5475096A (en) 1990-06-11 1995-12-12 University Research Corporation Nucleic acid ligands
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US5674685A (en) 1990-06-11 1997-10-07 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
US5654151A (en) 1990-06-11 1997-08-05 Nexstar Pharmaceuticals, Inc. High affinity HIV Nucleocapsid nucleic acid ligands
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5459015A (en) 1990-06-11 1995-10-17 Nexstar Pharmaceuticals, Inc. High-affinity RNA ligands of basic fibroblast growth factor
US5637459A (en) 1990-06-11 1997-06-10 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chimeric selex
US5763173A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand inhibitors to DNA polymerases
US6395888B1 (en) * 1996-02-01 2002-05-28 Gilead Sciences, Inc. High affinity nucleic acid ligands of complement system proteins
US5503978A (en) 1990-06-11 1996-04-02 University Research Corporation Method for identification of high affinity DNA ligands of HIV-1 reverse transcriptase
US5683867A (en) 1990-06-11 1997-11-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: blended SELEX
US5648214A (en) 1990-06-11 1997-07-15 University Research Corporation High-affinity oligonucleotide ligands to the tachykinin substance P
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US5789157A (en) 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue selex
US6140490A (en) * 1996-02-01 2000-10-31 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands of complement system proteins
US5496938A (en) 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US5861254A (en) 1997-01-31 1999-01-19 Nexstar Pharmaceuticals, Inc. Flow cell SELEX
US5707796A (en) 1990-06-11 1998-01-13 Nexstar Pharmaceuticals, Inc. Method for selecting nucleic acids on the basis of structure
US5635615A (en) 1990-06-11 1997-06-03 Nexstar Pharmaceuticals, Inc. High affinity HIV nucleocapsid nucleic acid ligands
US5580737A (en) 1990-06-11 1996-12-03 Nexstar Pharmaceuticals, Inc. High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5705337A (en) 1990-06-11 1998-01-06 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: chemi-SELEX
US5668264A (en) 1990-06-11 1997-09-16 Nexstar Pharmaceuticals, Inc. High affinity PDGF nucleic acid ligands
AU8547691A (en) 1990-09-21 1992-04-15 Fred Hutchinson Cancer Research Center Protein sequence-specific oligonucleotide sequences
DE552178T1 (de) 1990-10-12 1994-02-03 Max Planck Gesellschaft Abgeänderte ribozyme.
AU1456092A (en) 1991-02-21 1992-09-15 Gilead Sciences, Inc. Aptamers specific for thrombin and methods of use
AU1435492A (en) 1991-02-21 1992-09-15 Gilead Sciences, Inc. Aptamer specific for biomolecules and method of making
US5338671A (en) 1992-10-07 1994-08-16 Eastman Kodak Company DNA amplification with thermostable DNA polymerase and polymerase inhibiting antibody
TW239160B (es) * 1992-10-27 1995-01-21 Procter & Gamble
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
US5817635A (en) 1993-08-09 1998-10-06 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Modified ribozymes
US5681702A (en) * 1994-08-30 1997-10-28 Chiron Corporation Reduction of nonspecific hybridization by using novel base-pairing schemes
US6013443A (en) 1995-05-03 2000-01-11 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: tissue SELEX
DE69636656T2 (de) 1995-06-02 2007-10-04 Gilead Sciences, Inc., Foster City Oligonukleotidliganden mit hoher affinität für pdgf
US6111095A (en) * 1995-06-07 2000-08-29 Merck & Co., Inc. Capped synthetic RNA, analogs, and aptamers
US6229002B1 (en) 1995-06-07 2001-05-08 Nexstar Pharmaceuticlas, Inc. Platelet derived growth factor (PDGF) nucleic acid ligand complexes
JP4335975B2 (ja) 1995-06-07 2009-09-30 ギリード・サイエンシズ・インコーポレーテッド Ｄｎａポリメラーゼに対する結合・阻害核酸リガンド
KR100514929B1 (ko) 1996-10-25 2005-09-15 길리애드 사이언시즈, 인코포레이티드 혈관내피 성장인자 핵산 리간드 복합체
US6051698A (en) 1997-06-06 2000-04-18 Janjic; Nebojsa Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US7419663B2 (en) 1998-03-20 2008-09-02 Genentech, Inc. Treatment of complement-associated disorders
US6329145B1 (en) * 1999-02-09 2001-12-11 Gilead Science, Inc. Determining non-nucleic acid molecule binding to target by competition with nucleic acid ligand
US6573299B1 (en) 1999-09-20 2003-06-03 Advanced Medical Instruments Method and compositions for treatment of the aging eye
JP2004532022A (ja) * 2001-03-26 2004-10-21 サーナ・セラピューティクス・インコーポレイテッド Ｂ型肝炎ウイルスおよびｃ型肝炎ウイルスの複製のオリゴヌクレオチド媒介性阻害
CA2487809A1 (en) * 2002-06-18 2003-12-24 Archemix Corp. Aptamer-toxin molecules and methods for using same
US20040249130A1 (en) * 2002-06-18 2004-12-09 Martin Stanton Aptamer-toxin molecules and methods for using same
US7803931B2 (en) 2004-02-12 2010-09-28 Archemix Corp. Aptamer therapeutics useful in the treatment of complement-related disorders

Also Published As

Publication number Publication date
PL2860251T3 (pl) 2019-02-28
US7579456B2 (en) 2009-08-25
WO2005079363A2 (en) 2005-09-01
HUE038239T2 (hu) 2018-10-29
WO2005079363A3 (en) 2009-05-14
EP3385384A1 (en) 2018-10-10
PT3385384T (pt) 2020-06-30
DK1727567T3 (da) 2013-10-14
JP2007527714A (ja) 2007-10-04
PT2860251T (pt) 2018-06-07
US7538211B2 (en) 2009-05-26
ES2531075T3 (es) 2015-03-10
ES2808955T3 (es) 2021-03-02
CY1120384T1 (el) 2019-07-10
SI3385384T1 (sl) 2020-12-31
EP1727567B1 (en) 2013-07-03
LT2860251T (lt) 2018-07-10
EP2578683B1 (en) 2014-11-26
JP5242918B2 (ja) 2013-07-24
EP1727567A4 (en) 2010-10-13
EP2860251A1 (en) 2015-04-15
EP3736335A1 (en) 2020-11-11
ES2429442T3 (es) 2013-11-14
HK1210495A1 (en) 2016-04-22
EP1727567A2 (en) 2006-12-06
DK3385384T3 (da) 2020-06-29
TR201808488T4 (tr) 2018-07-23
CY1123503T1 (el) 2022-03-24
EP2578683B9 (en) 2015-04-15
US20060105980A1 (en) 2006-05-18
HK1183896A1 (en) 2014-01-10
HUE050481T2 (hu) 2020-12-28
SI2860251T1 (en) 2018-07-31
PL3385384T3 (pl) 2021-03-08
LT3385384T (lt) 2020-09-25
EP2860251B1 (en) 2018-04-11
EP2578683A1 (en) 2013-04-10
CY1114443T1 (el) 2016-08-31
EP3385384B1 (en) 2020-04-08
PT1727567E (pt) 2013-10-14
US20070048248A1 (en) 2007-03-01
DK2860251T3 (en) 2018-06-06

Similar Documents

Publication Publication Date Title
ES2674129T3 (es) Agentes terapéuticos de base aptámeros útiles en el tratamiento de trastornos relacionados con complemento
EA200900782A1 (ru) Композиции и способы, предназначенные для лечения мышечных и сердечно-сосудистых нарушений
MY157715A (en) Cytotoxic agents comprising new tomaymycin derivatives and their therapeutic use
ATE502633T1 (de) Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
CY1115286T1 (el) Μεθοδοι θεραπευτικης αγωγης της νοσου toy parkinson
TW200640893A (en) Cytotoxic agents comprising new C-2 modified taxanes
MA27838A1 (fr) Traitement d'une maladie auto-immune chez un patient presentant une reponse inadequate a un inhibiteur de tnf-alpha
NO20073033L (no) Cytotoksiske midler innbefattende nye taksaner
DK1649017T3 (da) Anvendelse af RNA i inhiberende PARP aktivitet til fremstillingen af et lægemiddel til behandlingen af cancer
EA201490993A1 (ru) МОДИФИЦИРОВАННЫЕ СРЕДСТВА РНКи
NO20072558L (no) Mitotiske kineseinhibitorer og fremgangsmater for anvendelse derav
EA200901211A1 (ru) Антигены белка с5 и их применение
EA200802213A1 (ru) Способы лечения заболеваний крови
MX2010002732A (es) Inhibidores de f1f0-atpasa y metodos relacionados.
DE602007014186D1 (de) Triazin-11-beta-hydroxysteroid-dehydrogenase-artige hemmer
ECSP078060A (es) 2,4-diamino-pirimidinas como inhibidores de aurora
CR9078A (es) Derivado de bencimidazol ariloxi-sustituidos
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
TW200639155A (en) Thiazolidinones, their production and use as pharmaceutical agents
RU2007122391A (ru) S-миртазапин для лечения приливов
TW200612940A (en) Substituted tetrahydroisoquinolines as mmp inhibitors, process for their preparation and their use as medicament
TW200611693A (en) GPR35 and modulators thereof for the treatment of metabolic-related disorders
AR060312A1 (es) Metodos para regular renalasa (monoamina oxidasa c)
UY27074A1 (es) Derivados de aminotriazolopiridina
PA8776601A1 (es) Utilización de 4-ciclopropilmetoxi-n-(3,5-dicloro-1- oxido-piridin-4-il)-5(metoxi)piridin-2-carboxamida para el tratamiento de los traumatismos de la medula espinal